100
Participants
Start Date
April 4, 2022
Primary Completion Date
May 31, 2028
Study Completion Date
May 31, 2028
No Intervention
All subjects that previously received RGX-314 in a parent study
Retinovitreous Associates, LTD, Philadelphia
Cumberland Valley Retina Consultants, Hagerstown
Duke University, Durham
Charles Retina Institute, P.C, Germantown
University Retina and Macula Associates, PC, Oak Forest
Retina Consultants of Texas, The Woodlands
Austin Clinical Research, Austin
Retinal Research Institute, LLC, Phoenix
Vision Research Center Eye Associates of New Mexico, Albuquerque
Sierra eye Associates, Reno
American Institute of Research, Los Angeles
Retina-Vitreous Associates Medical Group, Beverly Hills
California Eye Specialists Medical Group, Inc, Pasadena
Retina Consultants San Diego, Poway
California Retina Consultants CRC, Santa Barbara
California Retina Consultants, Bakersfield
Northern California Retina Vitreous Associates Medical Group Inc, Mountain View
Ophthalmic Consultants of Boston, Boston
New Jersey Retina, Teaneck
Lead Sponsor
AbbVie
INDUSTRY